Spyre Therapeutics (SYRE) Non Operating Income (2015 - 2026)

Spyre Therapeutics has reported Non Operating Income for 12 years, with the latest figure at -$30.4 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 445.81% year-over-year to -$30.4 million; the trailing twelve-month figure through Mar 2026 stood at -$15.6 million (down 257.72% YoY), and the FY2025 full-year result was $29.5 million, up 4818.03% from the prior year.
• Non Operating Income for Q1 2026 stood at -$30.4 million, roughly flat from -$30.2 million in the prior quarter.
• The five-year high for Non Operating Income was $45.7 million in Q3 2025, with the low at -$98.8 million in Q4 2023.
• Historically, Non Operating Income has averaged -$5.7 million across 5 years, with a median of $109000.0 in 2022.
• The largest YoY upside for Non Operating Income was 6860.0% in 2023 against a maximum downside of 26230.95% in 2023.
• Spyre Therapeutics' Non Operating Income stood at $378000.0 in 2022, then tumbled by 26230.95% to -$98.8 million in 2023, then jumped by 120.75% to $20.5 million in 2024, then slumped by 247.57% to -$30.2 million in 2025, then decreased by 0.38% to -$30.4 million in 2026.
• The last three Non Operating Income figures came in at -$30.4 million (Q1 2026), -$30.2 million (Q4 2025), and $45.7 million (Q3 2025), per Business Quant data.